Company Intelligence
CSPC Pharmaceutical Group
石药集团
HK: 1093Shijiazhuang, Hebei, ChinaFounded 1997
BIOSECURE
No Known BCC Exposure
CSPC is a drug innovator, not a CDMO/CRO. No BIOSECURE exposure. Licensing deals with CSPC do not create federal contracting risk.
1
Tracked Deals
4
Therapeutic Areas
3
Modalities
Overview
CSPC Pharmaceutical Group (石药集团) is a major Chinese pharmaceutical company with strengths in both innovative and generic drugs. CSPC's cardiovascular and metabolic disease pipeline has attracted significant Western interest, culminating in the AstraZeneca partnership — the largest headline deal value in China out-licensing history at $18.5B.
Key Facts
- AstraZeneca-CSPC $18.5B deal is the largest headline value in China out-licensing history
- Novel lipoprotein disruptor for cardiovascular/metabolic disease attracted AZ's interest
- Strong medicinal chemistry capabilities — demonstrates China innovation beyond biologics
- One of China's largest pharmaceutical companies by revenue ($4B+ in 2025)
Key Deals
| Partner | Date | Value | Asset |
|---|---|---|---|
| AstraZeneca | Oct 2025 | $18.5B | Small molecule lipoprotein disruptor (cardiovascular/metabolic) |
Corporate Structure
Hong Kong-listed holding company. Operating subsidiaries in mainland China. No VIE structure. Major shareholder: Cai Dongchen (蔡东晨), founder and chairman.